Subject: Smallcap Discoveries: Rx Biosyent (RX-TSX.V) Interview with CEO Rene Goehrum

Smallcap Discoveries:
Rx Biosyent (RX-TSX.V) Interview with CEO Rene Goehrum
On March 18th, we had an interview with Rene Goehrum of Rx Biosyent and below is a short summary on the company and our video interview.

Aout BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,740,775 common shares outstanding

Video Interview:
After our interviews, we host a session with the live participants to provide our thoughts on the Company as well as commentary on companies from both the Select Portfolio and Select Watchlist.

86 East 23rd Ave, v5v 1w9, Vancouver, Canada
You may unsubscribe or change your contact details at any time.